How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?

Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibro...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine research Vol. 12; no. 10; pp. 647 - 654
Main Authors da Silveira, Maria Mariana Barros Melo, Cabral, Joao Victor Batista, Souza, Bruno de Melo, Hazime, Louis Hussein Patu, Araujo, Sara Larissa de Melo, Xavier, Amanda Tavares, Mendes Filho, Edivaldo Bezerra, Vasconcelos, Luydson Richardson da Silva, Sobral Filho, Dario Celestino, de Oliveira, Dinaldo Cavalcanti
Format Journal Article
LanguageEnglish
Published Elmer Press 2020
Subjects
Review
Online AccessGet full text

Cover

More Information
Summary:Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1918-3003
1918-3011
DOI:10.14740/jocmr4313